<?xml version="1.0" encoding="UTF-8"?>
<drug type="biotech" created="2016-11-18" updated="2019-12-02">
  <drugbank-id primary="true">DB13148</drugbank-id>
  <name>Coagulation factor X human</name>
  <description>Coagulation Factor X (Human), is a plasma-derived human blood coagulation factor is used by adults and children (aged 12 years and above) with hereditary Factor X deficiency. However its use is limited in the perioperative setting for the management of bleeding in major surgery in patients with moderate and severe hereditary Factor X deficiency. &#13;
&#13;
Coagulation Factor X is a vitamin K-dependent, liver-produced serine protease that serves as the first enzyme in the coagulation cascade to form fibrin. It is a two-chain glycoprotein with the molecular weight of approximately 59 kDa [A31472]. While Factor X normally circulates in the plasma as inactive molecules, the activation of Factor X is involved in both the intrinsic and extrinsic coagulation pathways. Inherited factor X deficiency is a rare autosomal recessive bleeding disorder that is estimated to occur in 1:1 000 000 individuals up to 1:500 carriers [A31471]. Administration of coagulation Factor X from healthy donor serves to restore and achieve effective hemostasis. &#13;
&#13;
Coagulation Factor X (Human) solution is approved by the FDA for intravenous injection under the market name Coagadex which contains normally 100 IU/mL of coagulation Factor X derived from healthy donors who have passed viral screening tests [FDA Label].</description>
  <cas-number/>
  <unii>HYF6HN9XGQ</unii>
  <state>solid</state>
  <groups>
    <group>approved</group>
    <group>investigational</group>
  </groups>
  <general-references>
    <articles>
      <article>
        <ref-id>A31471</ref-id>
        <pubmed-id>19141158</pubmed-id>
        <citation>Brown DL, Kouides PA: Diagnosis and treatment of inherited factor X deficiency. Haemophilia. 2008 Nov;14(6):1176-82. doi: 10.1111/j.1365-2516.2008.01856.x.</citation>
      </article>
      <article>
        <ref-id>A31472</ref-id>
        <pubmed-id>11867437</pubmed-id>
        <citation>Venkateswarlu D, Perera L, Darden T, Pedersen LG: Structure and dynamics of zymogen human blood coagulation factor X. Biophys J. 2002 Mar;82(3):1190-206. doi: 10.1016/S0006-3495(02)75476-3.</citation>
      </article>
      <article>
        <ref-id>A19411</ref-id>
        <pubmed-id>25535411</pubmed-id>
        <citation>Palta S, Saroa R, Palta A: Overview of the coagulation system. Indian J Anaesth. 2014 Sep;58(5):515-23. doi: 10.4103/0019-5049.144643.</citation>
      </article>
    </articles>
    <textbooks/>
    <links/>
    <attachments/>
  </general-references>
  <synthesis-reference/>
  <indication>Indicated in adults and children (aged 12 years and above) with hereditary Factor X deficiency for on-demand treatment and control of bleeding episodes, or for perioperative management of bleeding in patients with mild hereditary Factor X deficiency [FDA Label]. </indication>
  <pharmacodynamics>Clinical human coagulation Factor X solution increases plasma levels of Factor X and can temporarily correct the coagulation defect in these patients, as reflected by decrease in the activated Partial Thromboplastin Time (aPTT) and prothrombin time (PT) [FDA Label].</pharmacodynamics>
  <mechanism-of-action>Factor X is an inactive zymogen that is synthesized in the liver, which can be activated by Factor IXa (via the intrinsic pathway) or by Factor VIIa (via the extrinsic pathway). It is composed of a light chain which contains the Gla (glutamic acid) domain and two epidermal growth factor domains, and a heavy chain that contains the catalytic serine protease domain [A31471]. The conversion of inactive Factor X into the active form Factor Xa requires the cleavage of a 52-residue peptide from the heavy chain [FDA Label] and the release of 52-residue activation peptide that contains the His236, Asp228 and Ser379 catalytic site. This activation step can occur through the extrinsic or intrinsic pathway and is considered to be the first step in the common pathway to fibrin formation [A31471]. &#13;
&#13;
Factor Xa plays a critical initiation step of the coagulation pathway by cleaving and activating prothrombin to thrombin in complex with FVa, Ca2+ and phospholipids. This complex is also known as the prothrombinase complex. Thrombin then acts upon soluble fibrinogen and Factor XIII to generate a cross-linked fibrin clot [FDA Label, A19411]. </mechanism-of-action>
  <toxicity/>
  <metabolism/>
  <absorption>Following a single intravenous dose of 25 IU/kg, the mean peak plasma concentration (CV%) was 0.504 (17.2) IU/mL [FDA Label]. </absorption>
  <half-life>Following a single intravenous dose of 25 IU/kg, the mean plasma half-life (CV%) was 30.3 (22.8) hr [FDA Label].</half-life>
  <protein-binding/>
  <route-of-elimination/>
  <volume-of-distribution>Following a single intravenous dose of 25 IU/kg, the mean volume of distribution at steady state (CV%) was 56.3 (24.0) mL/kg [FDA Label]. </volume-of-distribution>
  <clearance>Following a single intravenous dose of 25 IU/kg, the mean total body clearance was 1.35 (21.7) mL/kg/hr [FDA Label].</clearance>
  <classification>
    <description/>
    <direct-parent>Peptides</direct-parent>
    <kingdom>Organic Compounds</kingdom>
    <superclass>Organic Acids</superclass>
    <class>Carboxylic Acids and Derivatives</class>
    <subclass>Amino Acids, Peptides, and Analogues</subclass>
  </classification>
  <salts/>
  <synonyms>
    <synonym language="english" coder="">Coagulation factor X</synonym>
    <synonym language="english" coder="">Coagulation factor X (human)</synonym>
    <synonym language="english" coder="">Factor X</synonym>
    <synonym language="english" coder="">Factor X (stuart prower factor)</synonym>
    <synonym language="english" coder="">Human coagulation factor X</synonym>
    <synonym language="english" coder="">Stuart-prower factor</synonym>
  </synonyms>
  <products>
    <product>
      <name>Beriplex P/n 1000</name>
      <labeller>Csl Behring</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02410826</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-11-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder, for solution</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Beriplex P/n 500</name>
      <labeller>Csl Behring</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02359251</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-07-28</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder, for solution</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Coagadex</name>
      <labeller>Bio Products Laboratory Limited</labeller>
      <ndc-id/>
      <ndc-product-code>64208-7752</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-10-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength>100 [iU]/1mL</strength>
      <route>Intravenous</route>
      <fda-application-number>BLA125506</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Coagadex</name>
      <labeller>Bio Products Laboratory Limited</labeller>
      <ndc-id/>
      <ndc-product-code>64208-7753</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-10-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength>100 [iU]/1mL</strength>
      <route>Intravenous</route>
      <fda-application-number>BLA125506</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Feiba Vh Immuno Anti Inhibitor</name>
      <labeller>Osterreichisches Institut Fur Haemoderivate Ges M.B.H.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00609137</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1986-12-31</started-marketing-on>
      <ended-marketing-on>1998-08-13</ended-marketing-on>
      <dosage-form>Powder, for solution</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Kcentra</name>
      <labeller>CSL Behring GmbH</labeller>
      <ndc-id/>
      <ndc-product-code>63833-386</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-04-29</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number>BLA125421</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Kcentra</name>
      <labeller>CSL Behring GmbH</labeller>
      <ndc-id/>
      <ndc-product-code>63833-387</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-12-13</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number>BLA125421</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Octaplex</name>
      <labeller>Octapharma Pharmazeutika Produktionsges M B H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02434970</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-08-11</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit; Powder, for solution</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Octaplex</name>
      <labeller>Octapharma Pharmazeutika Produktionsges M B H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02294664</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-07-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit; Powder, for solution</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
  </products>
  <international-brands/>
  <mixtures>
    <mixture>
      <name>Kcentra</name>
      <ingredients>Coagulation Factor IX Human + Coagulation factor VII human + Coagulation factor X human + Protein C + Protein S human + Prothrombin</ingredients>
    </mixture>
    <mixture>
      <name>Kcentra</name>
      <ingredients>Coagulation Factor IX Human + Coagulation factor VII human + Coagulation factor X human + Protein C + Protein S human + Prothrombin</ingredients>
    </mixture>
    <mixture>
      <name>Coagadex</name>
      <ingredients>Coagulation factor X human</ingredients>
    </mixture>
    <mixture>
      <name>Coagadex</name>
      <ingredients>Coagulation factor X human</ingredients>
    </mixture>
    <mixture>
      <name>Octaplex</name>
      <ingredients>Coagulation Factor IX Human + Coagulation factor VII human + Coagulation factor X human + Protein C + Protein S human + Prothrombin</ingredients>
    </mixture>
    <mixture>
      <name>Feiba Vh Immuno Anti Inhibitor</name>
      <ingredients>Antihemophilic factor human + Coagulation factor VII human + Coagulation factor X human + Factor IX Complex (Human) + Prothrombin</ingredients>
    </mixture>
    <mixture>
      <name>Beriplex P/n 500</name>
      <ingredients>Coagulation Factor IX Human + Coagulation factor VII human + Coagulation factor X human + Protein C + Protein S human + Prothrombin</ingredients>
    </mixture>
    <mixture>
      <name>Beriplex P/n 1000</name>
      <ingredients>Coagulation Factor IX Human + Coagulation factor VII human + Coagulation factor X human + Protein C + Protein S human + Prothrombin</ingredients>
    </mixture>
    <mixture>
      <name>Octaplex</name>
      <ingredients>Coagulation Factor IX Human + Coagulation factor VII human + Coagulation factor X human + Protein C + Protein S human + Prothrombin</ingredients>
    </mixture>
  </mixtures>
  <packagers/>
  <manufacturers/>
  <prices/>
  <categories>
    <category>
      <category>Amino Acids, Peptides, and Proteins</category>
      <mesh-id>D000602</mesh-id>
    </category>
    <category>
      <category>Biological Factors</category>
      <mesh-id>D001685</mesh-id>
    </category>
    <category>
      <category>Blood and Blood Forming Organs</category>
      <mesh-id/>
    </category>
    <category>
      <category>Blood Coagulation Factors</category>
      <mesh-id>D001779</mesh-id>
    </category>
    <category>
      <category>Blood Proteins</category>
      <mesh-id>D001798</mesh-id>
    </category>
    <category>
      <category>Factor X</category>
      <mesh-id>D005170</mesh-id>
    </category>
    <category>
      <category>Factor X, agonists</category>
      <mesh-id/>
    </category>
    <category>
      <category>Factor X, antagonists &amp; inhibitors</category>
      <mesh-id/>
    </category>
    <category>
      <category>Hemostatics</category>
      <mesh-id>D006490</mesh-id>
    </category>
    <category>
      <category>Increased Coagulation Activity</category>
      <mesh-id/>
    </category>
    <category>
      <category>Proteins</category>
      <mesh-id>D011506</mesh-id>
    </category>
  </categories>
  <affected-organisms>
    <affected-organism>Humans and other mammals</affected-organism>
  </affected-organisms>
  <dosages>
    <dosage>
      <form>Kit</form>
      <route>Intravenous</route>
      <strength>100 [iU]/1mL</strength>
    </dosage>
    <dosage>
      <form>Powder, for solution</form>
      <route>Intravenous</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Kit</form>
      <route>Intravenous</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Kit; powder, for solution</form>
      <route>Intravenous</route>
      <strength/>
    </dosage>
  </dosages>
  <atc-codes>
    <atc-code code="B02BD13">
      <level code="B02BD">Blood coagulation factors</level>
      <level code="B02B">VITAMIN K AND OTHER HEMOSTATICS</level>
      <level code="B02">ANTIHEMORRHAGICS</level>
      <level code="B">BLOOD AND BLOOD FORMING ORGANS</level>
    </atc-code>
  </atc-codes>
  <ahfs-codes/>
  <pdb-entries/>
  <fda-label>//s3-us-west-2.amazonaws.com/drugbank/fda_labels/DB13148.pdf?1513374082</fda-label>
  <patents/>
  <food-interactions/>
  <drug-interactions>
    <drug-interaction>
      <drugbank-id>DB00513</drugbank-id>
      <name>Aminocaproic acid</name>
      <description>The risk or severity of adverse effects can be increased when Aminocaproic acid is combined with Coagulation factor X human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00058</drugbank-id>
      <name>Alpha-1-proteinase inhibitor</name>
      <description>Alpha-1-proteinase inhibitor may increase the thrombogenic activities of Coagulation factor X human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00170</drugbank-id>
      <name>Menadione</name>
      <description>Menadione may increase the thrombogenic activities of Coagulation factor X human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00302</drugbank-id>
      <name>Tranexamic acid</name>
      <description>Tranexamic acid may increase the thrombogenic activities of Coagulation factor X human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06692</drugbank-id>
      <name>Aprotinin</name>
      <description>Aprotinin may increase the thrombogenic activities of Coagulation factor X human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11091</drugbank-id>
      <name>Hydrogen peroxide</name>
      <description>Hydrogen peroxide may increase the thrombogenic activities of Coagulation factor X human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13244</drugbank-id>
      <name>Aminomethylbenzoic acid</name>
      <description>Aminomethylbenzoic acid may increase the thrombogenic activities of Coagulation factor X human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13729</drugbank-id>
      <name>Camostat</name>
      <description>Camostat may increase the thrombogenic activities of Coagulation factor X human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12726</drugbank-id>
      <name>Monteplase</name>
      <description>The therapeutic efficacy of Coagulation factor X human can be decreased when used in combination with Monteplase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00001</drugbank-id>
      <name>Lepirudin</name>
      <description>The therapeutic efficacy of Coagulation factor X human can be decreased when used in combination with Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00006</drugbank-id>
      <name>Bivalirudin</name>
      <description>The therapeutic efficacy of Coagulation factor X human can be decreased when used in combination with Bivalirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00009</drugbank-id>
      <name>Alteplase</name>
      <description>The therapeutic efficacy of Coagulation factor X human can be decreased when used in combination with Alteplase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00013</drugbank-id>
      <name>Urokinase</name>
      <description>The therapeutic efficacy of Coagulation factor X human can be decreased when used in combination with Urokinase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00015</drugbank-id>
      <name>Reteplase</name>
      <description>The therapeutic efficacy of Coagulation factor X human can be decreased when used in combination with Reteplase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00029</drugbank-id>
      <name>Anistreplase</name>
      <description>The therapeutic efficacy of Coagulation factor X human can be decreased when used in combination with Anistreplase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00031</drugbank-id>
      <name>Tenecteplase</name>
      <description>The therapeutic efficacy of Coagulation factor X human can be decreased when used in combination with Tenecteplase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00054</drugbank-id>
      <name>Abciximab</name>
      <description>The therapeutic efficacy of Coagulation factor X human can be decreased when used in combination with Abciximab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00055</drugbank-id>
      <name>Drotrecogin alfa</name>
      <description>The therapeutic efficacy of Coagulation factor X human can be decreased when used in combination with Drotrecogin alfa.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00086</drugbank-id>
      <name>Streptokinase</name>
      <description>The therapeutic efficacy of Coagulation factor X human can be decreased when used in combination with Streptokinase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00261</drugbank-id>
      <name>Anagrelide</name>
      <description>The therapeutic efficacy of Coagulation factor X human can be decreased when used in combination with Anagrelide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00266</drugbank-id>
      <name>Dicoumarol</name>
      <description>The therapeutic efficacy of Coagulation factor X human can be decreased when used in combination with Dicoumarol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00278</drugbank-id>
      <name>Argatroban</name>
      <description>The therapeutic efficacy of Coagulation factor X human can be decreased when used in combination with Argatroban.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00407</drugbank-id>
      <name>Ardeparin</name>
      <description>The therapeutic efficacy of Coagulation factor X human can be decreased when used in combination with Ardeparin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00498</drugbank-id>
      <name>Phenindione</name>
      <description>The therapeutic efficacy of Coagulation factor X human can be decreased when used in combination with Phenindione.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00569</drugbank-id>
      <name>Fondaparinux</name>
      <description>The therapeutic efficacy of Coagulation factor X human can be decreased when used in combination with Fondaparinux.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00682</drugbank-id>
      <name>Warfarin</name>
      <description>The therapeutic efficacy of Coagulation factor X human can be decreased when used in combination with Warfarin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00686</drugbank-id>
      <name>Pentosan polysulfate</name>
      <description>The therapeutic efficacy of Coagulation factor X human can be decreased when used in combination with Pentosan polysulfate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00945</drugbank-id>
      <name>Acetylsalicylic acid</name>
      <description>The therapeutic efficacy of Coagulation factor X human can be decreased when used in combination with Acetylsalicylic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00946</drugbank-id>
      <name>Phenprocoumon</name>
      <description>The therapeutic efficacy of Coagulation factor X human can be decreased when used in combination with Phenprocoumon.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00975</drugbank-id>
      <name>Dipyridamole</name>
      <description>The therapeutic efficacy of Coagulation factor X human can be decreased when used in combination with Dipyridamole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01088</drugbank-id>
      <name>Iloprost</name>
      <description>The therapeutic efficacy of Coagulation factor X human can be decreased when used in combination with Iloprost.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01109</drugbank-id>
      <name>Heparin</name>
      <description>The therapeutic efficacy of Coagulation factor X human can be decreased when used in combination with Heparin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01225</drugbank-id>
      <name>Enoxaparin</name>
      <description>The therapeutic efficacy of Coagulation factor X human can be decreased when used in combination with Enoxaparin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01240</drugbank-id>
      <name>Epoprostenol</name>
      <description>The therapeutic efficacy of Coagulation factor X human can be decreased when used in combination with Epoprostenol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01418</drugbank-id>
      <name>Acenocoumarol</name>
      <description>The therapeutic efficacy of Coagulation factor X human can be decreased when used in combination with Acenocoumarol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB03410</drugbank-id>
      <name>4-hydroxycoumarin</name>
      <description>The therapeutic efficacy of Coagulation factor X human can be decreased when used in combination with 4-hydroxycoumarin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04665</drugbank-id>
      <name>Coumarin</name>
      <description>The therapeutic efficacy of Coagulation factor X human can be decreased when used in combination with Coumarin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04898</drugbank-id>
      <name>Ximelagatran</name>
      <description>The therapeutic efficacy of Coagulation factor X human can be decreased when used in combination with Ximelagatran.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04925</drugbank-id>
      <name>Desmoteplase</name>
      <description>The therapeutic efficacy of Coagulation factor X human can be decreased when used in combination with Desmoteplase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04932</drugbank-id>
      <name>Defibrotide</name>
      <description>The therapeutic efficacy of Coagulation factor X human can be decreased when used in combination with Defibrotide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05099</drugbank-id>
      <name>Ancrod</name>
      <description>The therapeutic efficacy of Coagulation factor X human can be decreased when used in combination with Ancrod.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05229</drugbank-id>
      <name>Beraprost</name>
      <description>The therapeutic efficacy of Coagulation factor X human can be decreased when used in combination with Beraprost.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05254</drugbank-id>
      <name>Fibrinolysin</name>
      <description>The therapeutic efficacy of Coagulation factor X human can be decreased when used in combination with Fibrinolysin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06209</drugbank-id>
      <name>Prasugrel</name>
      <description>The therapeutic efficacy of Coagulation factor X human can be decreased when used in combination with Prasugrel.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06228</drugbank-id>
      <name>Rivaroxaban</name>
      <description>The therapeutic efficacy of Coagulation factor X human can be decreased when used in combination with Rivaroxaban.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06271</drugbank-id>
      <name>Sulodexide</name>
      <description>The therapeutic efficacy of Coagulation factor X human can be decreased when used in combination with Sulodexide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06406</drugbank-id>
      <name>Idraparinux</name>
      <description>The therapeutic efficacy of Coagulation factor X human can be decreased when used in combination with Idraparinux.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06441</drugbank-id>
      <name>Cangrelor</name>
      <description>The therapeutic efficacy of Coagulation factor X human can be decreased when used in combination with Cangrelor.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06543</drugbank-id>
      <name>Astaxanthin</name>
      <description>The therapeutic efficacy of Coagulation factor X human can be decreased when used in combination with Astaxanthin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06605</drugbank-id>
      <name>Apixaban</name>
      <description>The therapeutic efficacy of Coagulation factor X human can be decreased when used in combination with Apixaban.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06635</drugbank-id>
      <name>Otamixaban</name>
      <description>The therapeutic efficacy of Coagulation factor X human can be decreased when used in combination with Otamixaban.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06679</drugbank-id>
      <name>Amediplase</name>
      <description>The therapeutic efficacy of Coagulation factor X human can be decreased when used in combination with Amediplase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06695</drugbank-id>
      <name>Dabigatran etexilate</name>
      <description>The therapeutic efficacy of Coagulation factor X human can be decreased when used in combination with Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06754</drugbank-id>
      <name>Danaparoid</name>
      <description>The therapeutic efficacy of Coagulation factor X human can be decreased when used in combination with Danaparoid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06779</drugbank-id>
      <name>Dalteparin</name>
      <description>The therapeutic efficacy of Coagulation factor X human can be decreased when used in combination with Dalteparin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06822</drugbank-id>
      <name>Tinzaparin</name>
      <description>The therapeutic efficacy of Coagulation factor X human can be decreased when used in combination with Tinzaparin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB07767</drugbank-id>
      <name>Ferulic acid</name>
      <description>The therapeutic efficacy of Coagulation factor X human can be decreased when used in combination with Ferulic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08496</drugbank-id>
      <name>(R)-warfarin</name>
      <description>The therapeutic efficacy of Coagulation factor X human can be decreased when used in combination with (R)-warfarin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08794</drugbank-id>
      <name>Ethyl biscoumacetate</name>
      <description>The therapeutic efficacy of Coagulation factor X human can be decreased when used in combination with Ethyl biscoumacetate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08813</drugbank-id>
      <name>Nadroparin</name>
      <description>The therapeutic efficacy of Coagulation factor X human can be decreased when used in combination with Nadroparin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08814</drugbank-id>
      <name>Triflusal</name>
      <description>The therapeutic efficacy of Coagulation factor X human can be decreased when used in combination with Triflusal.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08816</drugbank-id>
      <name>Ticagrelor</name>
      <description>The therapeutic efficacy of Coagulation factor X human can be decreased when used in combination with Ticagrelor.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08994</drugbank-id>
      <name>Ditazole</name>
      <description>The therapeutic efficacy of Coagulation factor X human can be decreased when used in combination with Ditazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09030</drugbank-id>
      <name>Vorapaxar</name>
      <description>The therapeutic efficacy of Coagulation factor X human can be decreased when used in combination with Vorapaxar.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09075</drugbank-id>
      <name>Edoxaban</name>
      <description>The therapeutic efficacy of Coagulation factor X human can be decreased when used in combination with Edoxaban.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09125</drugbank-id>
      <name>Potassium citrate</name>
      <description>The therapeutic efficacy of Coagulation factor X human can be decreased when used in combination with Potassium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09154</drugbank-id>
      <name>Sodium citrate</name>
      <description>The therapeutic efficacy of Coagulation factor X human can be decreased when used in combination with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09255</drugbank-id>
      <name>Dextran</name>
      <description>The therapeutic efficacy of Coagulation factor X human can be decreased when used in combination with Dextran.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09258</drugbank-id>
      <name>Bemiparin</name>
      <description>The therapeutic efficacy of Coagulation factor X human can be decreased when used in combination with Bemiparin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09259</drugbank-id>
      <name>Reviparin</name>
      <description>The therapeutic efficacy of Coagulation factor X human can be decreased when used in combination with Reviparin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09260</drugbank-id>
      <name>Parnaparin</name>
      <description>The therapeutic efficacy of Coagulation factor X human can be decreased when used in combination with Parnaparin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09261</drugbank-id>
      <name>Certoparin</name>
      <description>The therapeutic efficacy of Coagulation factor X human can be decreased when used in combination with Certoparin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11095</drugbank-id>
      <name>Desirudin</name>
      <description>The therapeutic efficacy of Coagulation factor X human can be decreased when used in combination with Desirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11154</drugbank-id>
      <name>Zinc citrate</name>
      <description>The therapeutic efficacy of Coagulation factor X human can be decreased when used in combination with Zinc citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11166</drugbank-id>
      <name>Antithrombin Alfa</name>
      <description>The therapeutic efficacy of Coagulation factor X human can be decreased when used in combination with Antithrombin Alfa.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11598</drugbank-id>
      <name>Antithrombin III human</name>
      <description>The therapeutic efficacy of Coagulation factor X human can be decreased when used in combination with Antithrombin III human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11984</drugbank-id>
      <name>Letaxaban</name>
      <description>The therapeutic efficacy of Coagulation factor X human can be decreased when used in combination with Letaxaban.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12289</drugbank-id>
      <name>Darexaban</name>
      <description>The therapeutic efficacy of Coagulation factor X human can be decreased when used in combination with Darexaban.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12364</drugbank-id>
      <name>Betrixaban</name>
      <description>The therapeutic efficacy of Coagulation factor X human can be decreased when used in combination with Betrixaban.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12598</drugbank-id>
      <name>Nafamostat</name>
      <description>The therapeutic efficacy of Coagulation factor X human can be decreased when used in combination with Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12831</drugbank-id>
      <name>Gabexate</name>
      <description>The therapeutic efficacy of Coagulation factor X human can be decreased when used in combination with Gabexate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13136</drugbank-id>
      <name>Fluindione</name>
      <description>The therapeutic efficacy of Coagulation factor X human can be decreased when used in combination with Fluindione.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13199</drugbank-id>
      <name>Brinase</name>
      <description>The therapeutic efficacy of Coagulation factor X human can be decreased when used in combination with Brinase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13275</drugbank-id>
      <name>Clorindione</name>
      <description>The therapeutic efficacy of Coagulation factor X human can be decreased when used in combination with Clorindione.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13347</drugbank-id>
      <name>Diphenadione</name>
      <description>The therapeutic efficacy of Coagulation factor X human can be decreased when used in combination with Diphenadione.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13451</drugbank-id>
      <name>Tioclomarol</name>
      <description>The therapeutic efficacy of Coagulation factor X human can be decreased when used in combination with Tioclomarol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13616</drugbank-id>
      <name>Melagatran</name>
      <description>The therapeutic efficacy of Coagulation factor X human can be decreased when used in combination with Melagatran.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13646</drugbank-id>
      <name>Saruplase</name>
      <description>The therapeutic efficacy of Coagulation factor X human can be decreased when used in combination with Saruplase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14055</drugbank-id>
      <name>(S)-Warfarin</name>
      <description>The therapeutic efficacy of Coagulation factor X human can be decreased when used in combination with (S)-Warfarin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14094</drugbank-id>
      <name>Tocopherylquinone</name>
      <description>The therapeutic efficacy of Coagulation factor X human can be decreased when used in combination with Tocopherylquinone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14598</drugbank-id>
      <name>Edetate calcium disodium anhydrous</name>
      <description>The therapeutic efficacy of Coagulation factor X human can be decreased when used in combination with Edetate calcium disodium anhydrous.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14600</drugbank-id>
      <name>Edetate disodium anhydrous</name>
      <description>The therapeutic efficacy of Coagulation factor X human can be decreased when used in combination with Edetate disodium anhydrous.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14726</drugbank-id>
      <name>Dabigatran</name>
      <description>The therapeutic efficacy of Coagulation factor X human can be decreased when used in combination with Dabigatran.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06294</drugbank-id>
      <name>Semuloparin</name>
      <description>The therapeutic efficacy of Coagulation factor X human can be decreased when used in combination with Semuloparin.</description>
    </drug-interaction>
  </drug-interactions>
  <sequences/>
  <experimental-properties>
    <property>
      <kind>Molecular Weight</kind>
      <value>59000.0</value>
      <source/>
    </property>
  </experimental-properties>
  <external-identifiers>
    <external-identifier>
      <resource>Drugs Product Database (DPD)</resource>
      <identifier>4229</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PubChem Substance</resource>
      <identifier>347911432</identifier>
    </external-identifier>
  </external-identifiers>
  <external-links/>
  <pathways/>
  <reactions/>
  <snp-effects/>
  <snp-adverse-drug-reactions/>
  <targets/>
  <enzymes/>
  <carriers/>
  <transporters/>
</drug>